Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Hervé, Barjat"'
Autor:
Amin Farshchi, Hervé Barjat, Stephen Checkley, Michael Leane, Mike Tobyn, Chris Morris, Furqan Tahir, Richard Anthony Storey, John F. Gamble, Toma Chitu, Neil Dawson, Andy Mitchell, Ana Patricia Ferreira, Kendal Pitt
Publikováno v:
Journal of Pharmaceutical Innovation. 16:181-196
Understanding and predicting the flow of bulk pharmaceutical materials could be key in enabling pharmaceutical manufacturing by continuous direct compression (CDC). This study examines whether, by taking powder and bulk measurements, and using statis
Autor:
Valerie S. Honndorf, Holger Schmidt, Hans F. Wehrl, Stefan Wiehr, Walter Ehrlichmann, Leticia Quintanilla-Martinez, Hervé Barjat, Sally-Ann Ricketts, Bernd J. Pichler
Publikováno v:
Molecular Imaging, Vol 14 (2015)
We aimed to quantitatively characterize the treatment effects of docetaxel in the HCT116 xenograft mouse model, applying diffusion-weighted magnetic resonance imaging (MRI) and positron emission tomography (PET) using 2-deoxy-2-[ 18 F]fluoro-D-glucos
Externí odkaz:
https://doaj.org/article/3b92a51d10184c80a7fbcfaa7a9761fc
Autor:
Ross A, Little, Hervé, Barjat, Jennifer I, Hare, Mary, Jenner, Yvonne, Watson, Susan, Cheung, Katherine, Holliday, Weijuan, Zhang, James P B, O'Connor, Simon T, Barry, Sanyogitta, Puri, Geoffrey J M, Parker, John C, Waterton
Publikováno v:
Magnetic resonance imaging. 46
Solid tumours exhibit enhanced vessel permeability and fenestrated endothelium to varying degree, but it is unknown how this varies in patients between and within tumour types. Dynamic contrast-enhanced (DCE) MRI provides a measure of perfusion and p
Autor:
Hervé Barjat, Urszula M. Polanska, Alison Pritchard, Sally-Ann Emmas, Kevin Hudson, Juliana Maynard, François-Xavier Blé, Urs Hancox, Emily Lawrie
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183048 (2017)
PLoS ONE
PLoS ONE
Background The phosphatidyl inositol 3 kinase (PI3K), AKT and mammalian target of rapamycin (mTOR) signal transduction pathway is frequently de-regulated and activated in human cancer and is an important therapeutic target. AZD8835 is a PI3K inhibito
Publikováno v:
In Chemical Physics Letters 1999 305(1):28-34
Autor:
Neil Woodhouse, Katherine F. Holliday, Susan Cheung, Hervé Barjat, James P B O'Connor, Marietta Scott, Josephine H. Naish, J.L. Ulloa, Gerard Thompson, Geoff J M Parker, Giovanni A Buonaccorsi, Inna V. Linnik, Timothy H Ward, Caroline Dive, Alan Jackson, John C. Waterton, Cassandra L Hodgkinson, Samantha J. Mills, Carsten Liess, Helen Young, Darren L. Roberts
Publikováno v:
Magnetic Resonance in Medicine. 71:1854-1862
PURPOSE: There is a clinical need for noninvasive, nonionizing imaging biomarkers of tumor hypoxia and oxygenation. We evaluated the relationship of T1 -weighted oxygen-enhanced magnetic resonance imaging (OE-MRI) measurements to histopathology measu
Autor:
Simon T. Barry, François-Xavier Blé, Emily Lawrie, Sally-Ann Emmas, Urs Hancox, Hervé Barjat, Deborah Oakes, Juliana Maynard, Urszula M. Polanska
Publikováno v:
EJNMMI Research
Background The phosphatidylinositol 3 kinase (PI3K) signalling pathway is frequently altered in human cancer and a promising therapeutic target. AZD8186 (AstraZeneca) is a PI3Kβ/δ inhibitor, currently in phase 1 clinical trials. 18F-fluorodeoxygluc
Autor:
Michael F. James, Simon T. Bate, Satheesh Maheswaran, Andreas Pohlmann, Derek L. G. Hill, Daniel Rueckert, Lorna Tilling, Sean C. Smart, Neil Upton, David R. Howlett, Jo Hajnal, Thomas Hartkens, Hervé Barjat, Jill C. Richardson
Publikováno v:
Brain Research. 1270:19-32
In humans, mutations of amyloid precursor protein (APP) and presenilins (PS) 1 and 2 are associated with amyloid deposition, brain structural change and cognitive decline, like in Alzheimer's disease (AD). Mice expressing these proteins have illumina
Autor:
Bernd J. Pichler, Valerie S. Honndorf, Hervé Barjat, Holger Schmidt, Hans F. Wehrl, Anke Stahlschmidt, Leticia Quintanilla-Martinez, Stefan Wiehr, Sally-Ann Emmas
Publikováno v:
Molecular imaging and biology. 18(2)
Positron emission tomography (PET) and diffusion-weighted MRI (DW-MRI) were used to characterize the treatment effects of the MEK1/2 inhibitor selumetinib (AZD6244), docetaxel, and their combination in HCT116 tumor-bearing mice on the molecular level
Autor:
Valerie S, Honndorf, Holger, Schmidt, Hans F, Wehrl, Stefan, Wiehr, Walter, Ehrlichmann, Leticia, Quintanilla-Martinez, Hervé, Barjat, Sally-Ann, Ricketts, Bernd J, Pichler
Publikováno v:
Molecular imaging. 13
We aimed to quantitatively characterize the treatment effects of docetaxel in the HCT116 xenograft mouse model, applying diffusion-weighted magnetic resonance imaging (MRI) and positron emission tomography (PET) using 2-deoxy-2-[¹⁸F]fluoro-d-gluco